Intellia Therapeutics (NTLA) Cash from Operations (2015 - 2026)
Intellia Therapeutics (NTLA) reported Cash from Operations of 117346000.0 for Q1 2026, up 21.21% year-over-year from 96814317.89 in Q1 2025, and down 69.37% quarter-over-quarter from 69285000.0 in Q4 2025.
Intellia Therapeutics (NTLA) Cash from Operations (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of Cash from Operations data on file, last reported at 117346000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 117346000.0, up 21.21% year-over-year; the trailing twelve-month figure through Mar 2026 was 363152000.0 (up 3.71% YoY), and the FY2025 annual result was 394736000.0, down 13.14% from the prior year.
- Cash from Operations slipped to 117346000.0 in Q1 2026 per NTLA's latest filing, from 69285000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 58186000.0 in Q2 2024 and troughed at 148930000.0 in Q1 2025.
- A 5-year average of 93431470.59 and a median of 89869000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations soared 35.58% in 2024, then sank 71.21% in 2025.
- A 5-year view of Cash from Operations shows it stood at 89869000.0 in 2022, then slipped by 3.54% to 93054000.0 in 2023, then advanced by 8.45% to 85195000.0 in 2024, then grew by 18.67% to 69285000.0 in 2025, then plunged by 69.37% to 117346000.0 in 2026.
- Business Quant data shows NTLA's Cash from Operations at 117346000.0 in Q1 2026, 69285000.0 in Q4 2025, and 76899000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -117.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.35 Mn |
| Mar 31, 2026 | -117.35 Mn |
| Dec 31, 2025 | -69.29 Mn |
| Dec 31, 2025 | -69.29 Mn |
| Sep 30, 2025 | -76.90 Mn |
| Sep 30, 2025 | -76.90 Mn |
| Jun 30, 2025 | -99.62 Mn |
| Jun 30, 2025 | -99.62 Mn |
| Mar 31, 2025 | -148.93 Mn |
| Mar 31, 2025 | -148.93 Mn |
| Dec 31, 2024 | -85.20 Mn |
| Dec 31, 2024 | -85.20 Mn |
| Sep 30, 2024 | -84.84 Mn |
| Sep 30, 2024 | -84.84 Mn |
| Jun 30, 2024 | -58.19 Mn |
| Jun 30, 2024 | -58.19 Mn |
| Mar 31, 2024 | -120.66 Mn |
| Mar 31, 2024 | -120.66 Mn |
| Dec 31, 2023 | -93.05 Mn |
| Dec 31, 2023 | -93.05 Mn |